scholarly journals Family history of breast or ovarian cancer modifies the risk of secondary leukemia after breast cancer: Results from a population-based study

2007 ◽  
Vol 122 (5) ◽  
pp. 1114-1117 ◽  
Author(s):  
Helena M. Verkooijen ◽  
Gerald Fioretta ◽  
Elisabetta Rapiti ◽  
Georges Vlastos ◽  
Isabelle Neyroud-Caspar ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Ovarian Cancer ◽  
Family History ◽  
Population Based ◽  
Secondary Leukemia ◽  
Population Based Study ◽  
History Of

Association of Parity and Ovarian Cancer Risk by Family History of Breast or Ovarian Cancer in a Population-Based Study of Postmenopausal Women

Epidemiology ◽  
2002 ◽  
Vol 13 (1) ◽  
pp. 66-71 ◽  
Author(s):  
Celine M. Vachon ◽  
Pamela J. Mink ◽  
Carol A. Janney ◽  
Thomas A. Sellers ◽  
James R. Cerhan ◽  
...  
Keyword(s):  
Ovarian Cancer ◽  
Family History ◽  
Cancer Risk ◽  
Postmenopausal Women ◽  
Population Based ◽  
Ovarian Cancer Risk ◽  
Population Based Study ◽  
History Of

Influence of young age at diagnosis and family history of breast or ovarian cancer on breast cancer outcomes in a population-based cohort study

2006 ◽  
Vol 105 (1) ◽  
pp. 69-80 ◽  
Author(s):  
Jane C. Figueiredo ◽  
Marguerite Ennis ◽  
Julia A. Knight ◽  
John R. McLaughlin ◽  
Nicky Hood ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Ovarian Cancer ◽  
Cohort Study ◽  
Family History ◽  
Population Based ◽  
Young Age ◽  
Age At Diagnosis ◽  
Cancer Outcomes ◽  
Breast Cancer Outcomes ◽  
History Of

Risk of ovarian cancer in breast-cancer patients with a family history of breast or ovarian cancer: a population-based cohort study

The Lancet ◽  
2002 ◽  
Vol 360 (9337) ◽  
pp. 891-894 ◽  
Author(s):  
Kjell Bergfeldt ◽  
Bosse Rydh ◽  
Fredrik Granath ◽  
Henrik Grönberg ◽  
Lukman Thalib ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Ovarian Cancer ◽  
Cohort Study ◽  
Family History ◽  
Cancer Patients ◽  
Population Based ◽  
Breast Cancer Patients ◽  
History Of

Association between Family History of Benign Prostatic Hyperplasia and Urinary Symptoms: Results of a Population-based Study

1995 ◽  
Vol 142 (9) ◽  
pp. 965-973 ◽  
Author(s):  
Rosebud O. Roberts ◽  
Thomas Rhodes ◽  
Laurel A. Panser ◽  
Cynthia J. Girman ◽  
Christopher G. Chute ◽  
...  
Keyword(s):  
Benign Prostatic Hyperplasia ◽  
Family History ◽  
Population Based ◽  
Prostatic Hyperplasia ◽  
Urinary Symptoms ◽  
Population Based Study ◽  
History Of

scholarly journals Prevalence of germline BRCA mutations in HER2-negative metastatic breast cancer: global results from the real-world, observational BREAKOUT study

2020 ◽  
Vol 22 (1) ◽  
Author(s):  
Joyce O’Shaughnessy ◽  
Christine Brezden-Masley ◽  
Marina Cazzaniga ◽  
Tapashi Dalvi ◽  
Graham Walker ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Risk Factors ◽  
Ovarian Cancer ◽  
Risk Factor ◽  
Metastatic Breast Cancer ◽  
Family History ◽  
Metastatic Breast ◽  
Cytotoxic Chemotherapy ◽  
First Line ◽  
History Of

Abstract Background The global observational BREAKOUT study investigated germline BRCA mutation (gBRCAm) prevalence in a population of patients with human epidermal growth factor receptor 2 (HER2)-negative metastatic breast cancer (MBC). Methods Eligible patients had initiated first-line cytotoxic chemotherapy for HER2-negative MBC within 90 days prior to enrollment. Hormone receptor (HR)-positive patients had experienced disease progression on or after prior endocrine therapy, or endocrine therapy was considered unsuitable. gBRCAm status was determined using baseline blood samples or prior germline test results. For patients with a negative gBRCAm test, archival tissue was tested for somatic BRCAm and homologous recombination repair mutations (HRRm). Details of first-line cytotoxic chemotherapy were also collected. Results Between March 2017 and April 2018, 384 patients from 14 countries were screened and consented to study enrollment; 341 patients were included in the full analysis set (median [range] age at enrollment: 56 [25–89] years; 256 (75.3%) postmenopausal). Overall, 33 patients (9.7%) had a gBRCAm (16 [4.7%] in gBRCA1 only, 12 [3.5%] in gBRCA2 only, and 5 [1.5%] in both gBRCA1 and gBRCA2). gBRCAm prevalence was similar in HR-positive and HR-negative patients. gBRCAm prevalence was 9.0% in European patients and 10.6% in Asian patients and was higher in patients aged ≤ 50 years at initial breast cancer (BC) diagnosis (12.9%) than patients aged > 50 years (5.4%). In patients with any risk factor for having a gBRCAm (family history of BC and/or ovarian cancer, aged ≤ 50 years at initial BC diagnosis, or triple-negative BC), prevalence was 10.4%, versus 5.8% in patients without these risk factors. HRRm prevalence was 14.1% (n = 9/64) in patients with germline BRCA wildtype. Conclusions Patient demographic and disease characteristics supported the association of a gBRCAm with younger age at initial BC diagnosis and family history of BC and/or ovarian cancer. gBRCAm prevalence in this cohort, not selected on the basis of risk factors for gBRCAm, was slightly higher than previous results suggested. gBRCAm prevalence among patients without a traditional risk factor for harboring a gBRCAm (5.8%) supports current guideline recommendations of routine gBRCAm testing in HER2-negative MBC, as these patients may benefit from poly(ADP-ribose) polymerase (PARP) inhibitor therapy. Trial registration NCT03078036.

scholarly journals Prevalence of Family History of Breast, Colorectal, Prostate, and Lung Cancer in a Population-Based Study

2010 ◽  
Vol 13 (7-8) ◽  
pp. 495-503 ◽  
Author(s):  
P.L. Mai ◽  
L. Wideroff ◽  
M.H. Greene ◽  
B.I. Graubard
Keyword(s):  
Lung Cancer ◽  
Family History ◽  
Population Based ◽  
Population Based Study ◽  
History Of
Sign in / Sign up

Export Citation Format

Share Document